These therapies offer strong glycemic control, weight loss benefits, and cardiovascular protection
There is an increased risk of dehydration because spironolactone is a diuretic and GLP-1 medications can reduce your urge to drink fluids
Cardiovascular safety clinical trials with arGLP1 in patients with type 2 diabetes mellitus
This research demonstrates that caregivers are willing to accept risk in exchange for a five-point improvement on the HQ-CT, a smaller marginal improvement than had been previously classified as meaningful
The STEP-1 trial published in the New England Journal of Medicine demonstrated 14.9% mean body weight reduction at 68 weeks on 2.4mg weekly semaglutide versus 2.4% with placebo
First, there is supporting evidence for the safety of GLP-1RAs across the board of cognitive and mental disorders, as we retrieved very few studies 44,159,181,182,193,205 suggesting worse neuropsychiatric outcomes associated with these medications (Tables 16, Fig